Zobrazeno 1 - 10
of 24
pro vyhledávání: '"A. N. Levanov"'
Autor:
A. M. Chekalov, M. O. Popova, I. V. Tsygankov, Yu. A. Rogacheva, N. P. Volkov, K. V. Lepik, M. V. Demchenkova, T. V. Schneider, Yu. V. Kopeikina, N. V. Medvedeva, I. S. Zyuzgin, E. S. Pavlyuchenko, A. N. Levanov, A. A. Myasnikov, E. V. Kariagina, N. B. Mikhailova, V. V. Baykov, A. D. Kulagin
Publikováno v:
Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, Vol 29, Iss 3, Pp 65-73 (2022)
Introduction. The risk of developing Hodgkin lymphoma (HL) with HIV infection is higher than in the general population, and the course of the disease itself is more aggressive. Currently, there is no unified approach to the treatment of HIV-related H
Externí odkaz:
https://doaj.org/article/ea9ed8309c9d4e90a602283379e9c436
Autor:
V. G. Potapenko, E. V. Baumert, A. A. Bobrova, R. V. Vashchenkov, N. V. Dorofeeva, K. D. Kaplanov, E. V. Karyagina, A. N. Levanov, A. S. Luchinin, S. I. Moiseev, A. V. Novitskii, A. S. Nizamutdinova, О. V. Pirogova, S. A. Povzun, М. V. Platonov, V. V. Porunova, D. А. Ptashnikov, V. V. Ryabchikova, S. Ya. Simeniv, I. А. Skorokhod, Е. А. Ukrainchenko, D. А. Chaginskaya, T. V. Shelekhova, M. N. Shirokova, A. A. Shutylev, N. V. Medvedeva
Publikováno v:
Онкогематология, Vol 17, Iss 3, Pp 48-61 (2022)
Background. The treatment options for patients with multiple myeloma who refractory to previous bortezomib and lenalidomide therapy are limited. Pomalidomide is ап immunomodulatory agent that was registered for the treatment of patients with double
Externí odkaz:
https://doaj.org/article/df93b644f61c43f1a2b7b163a8dd215b
Publikováno v:
Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье, Vol 0, Iss 2, Pp 113-121 (2021)
The aim of the study was to study the role of allogeneic transplantation of hematopoietic stem cells in a patient with the classic course of Hodgkin's lymphoma.Materials and methods. The work was carried out on the basis of the analysis of a clinical
Externí odkaz:
https://doaj.org/article/4b833bea1299414b824a6ee1fb99ae31
Autor:
K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 16, Iss 5, Pp 670-677 (2020)
Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29
Externí odkaz:
https://doaj.org/article/060e30356f7741b38e1ef181c3cd5e48
Autor:
E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov
Publikováno v:
Фармакоэкономика, Vol 14, Iss 2 (2021)
Background. The introduction of innovative drugs has significantly increased the treatment effectiveness in patients with relapsed/refractory multiple myeloma (RRMM), but the question of whether these expensive options can be financially secured rema
Externí odkaz:
https://doaj.org/article/5e3ab6bf218b4d07a9b2e4a646e4f6a2
Autor:
D. A. Sychev, A. N. Levanov, T. V. Shelekhova, P. O. Bochkov, N. Р. Denisenko, K. A. Ryzhikova, K. В. Mirzaev, E. A. Grishina, M. A. Gavrilov
Publikováno v:
Атеротромбоз, Vol 0, Iss 1, Pp 122-130 (2018)
Oral anticoagulants are widely used to prevent thromboembolic events in patients following total knee arthroplasty [1]. The genetic characteristics of patients affect the efficacy and safety of anticoagulants [2]. Dabigatran etexilate is a direct inh
Externí odkaz:
https://doaj.org/article/a03ad23a01f94d21a512f0a978fb7e54
Autor:
Dmitry Napalkov, Denis Andreev, R. M. Minnigulov, O. A. Baturina, K. A. Akmalova, I. N. Sychev, A. A. Sokolova, P. O. Bochkov, T. V. Shelekhova, A. I. Kalinkin, A. N. Levanov, D. V. Ivashchenko, A. A. Kachanova, A. I. Skripka, K. B. Mirzaev, D. A. Sychev, T. E. Morozova, I. V. Volodin, Elena A. Grishina
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 16, Iss 5, Pp 670-677 (2020)
Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs.Material and methods. The study enrolled 29
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b6a6258f815409ac85bb8991aa86c2
https://doi.org/10.20996/1819-6446-2020-10-05
https://doi.org/10.20996/1819-6446-2020-10-05
Publikováno v:
Kardiologiia. 17:84-93
In this review we present comparison of pharmacokinetics of novel oral anticoagulants (NOAC) dabigatran, rivaroxaban, apixaban, and edoxaban, principles of selection of a regimen of their dosing for phase III clinical trials in patients with atrial f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::608f3bdc3c426b24d166c11d45614ee5
https://doi.org/10.18087/cardio.2017.11.10058
https://doi.org/10.18087/cardio.2017.11.10058
Publikováno v:
Russian Heart Journal. 15:335-341
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9871851f6bac705c8a643248dbe84c0f
https://doi.org/10.18087/rhj.2016.5.2220
https://doi.org/10.18087/rhj.2016.5.2220
Publikováno v:
The European Proceedings of Social and Behavioural Sciences.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b265865e4bd44787bcc7b4f368ef0323
https://doi.org/10.15405/epsbs.2018.09.104
https://doi.org/10.15405/epsbs.2018.09.104